Adocia SA 

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins. Its clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analog lispro; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide M1Pram. The company's clinical pipeline also includes BioChaperone Glucagon, which is an aqueous formulation of human glucagon for the treatment of hypoglycemia. Its preclinical pipeline includes BioChaperone LisPram), which is a combination of rapid human insulin analogues and Pramlintide; BioChaperone Glargine GLP1 that is a combination of insulin glargine with GLP-1 receptor agonists for the treatment of diabetes; and BioChaperone Glucagon GLP1, which is a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was founded in 2005 and is headquartered in Lyon, France.